Search Medical Condition
Please enter condition
Please choose location

Jinshan, China Clinical Trials

A listing of Jinshan, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (11) clinical trials

Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B

The purpose of this study is to evaluate the safety and efficacy of Domestic Tenofovir Disoproxil Fumarate Tablets in Chinese patients with hepatitis B ,compared with Tenofovir Disoproxil Fumarate Tablets of Gilead.

Phase N/A

2.52 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Na ve and Treatment-Experienced Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

A Phase 3, double-blind (DB), placebo-controlled study to evaluate the efficacy and safety of ABT-493/ABT-530 in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human immunodeficiency virus (HIV) co-infection who are HCV treatment-nave or treatment-experienced with interferon (IFN) (alpha, beta or pegylated interferon ...

Phase

2.52 miles

Learn More »

A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B

This web-based database was launched on June 30, 2012 and consists of tertiary or secondary hospitals with special interest and expertise on managing hepatitis B patients across mainland China. The main inclusion criteria for this registration are HBsAg-positivity 6 months, HBeAg positive or negative, with or without cirrhosis, either treatment-nave ...

Phase N/A

2.52 miles

Learn More »

China Registry for Genetic / Metabolic Liver Diseases

This web-based database was launched on June 13, 2015 and consists of tertiary or secondary hospitals with special interest and expertise on managing genetic/metabolic liver diseases patients across mainland China. The main inclusion criteria for this registration are patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, ...

Phase N/A

2.52 miles

Learn More »

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Patients with chronic hepatitis B histologically confirmed of liver fibrosis S2/S3 (similar to metavir F2/F3, Ishak 2/3/4) are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus pegylated interferon (peg-IFN) for 1 year, ...

Phase

2.52 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Na ve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

This is a Phase 3, single-arm, open-label, multicenter study to evaluate the efficacy and safety of ABT-493/ABT-530 in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without Human Immunodeficiency Virus (HIV) co-infection who are HCV treatment-nave or treatment-experienced with interferon (IFN) (alpha, ...

Phase

2.52 miles

Learn More »

Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

Studies to assess the effectiveness of interventions to prevent HIV infection depend upon robust estimates of Baseline HIV incidence rates. The changing landscape of high-risk populations, as well as the evolution of biomedical pre-exposure prophylaxis (PrEP) interventions, requires a contemporary evaluation of HIV incidence as well as demographic, behavioral and ...

Phase N/A

2.52 miles

Learn More »

Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients

Patients who have completed 2-years entecavir-based treatment in Regress Study will receive another 5-years entecavir extension therapy. Patients will be assessed at baseline and every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan; A third liver biopsy will be performed at ...

Phase

2.52 miles

Learn More »

Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor

According to the Annual Report of Cancer Registration in China 2014, lung cancer, gastric cancer, liver cancer and colorectal cancer have become the top 4 solid tumors with the highest morbidity and mortality rates. So far, the main treatment modalities for these tumors have been surgery, radiotherapy and chemotherapy. However, ...

Phase

2.52 miles

Learn More »

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Treatment of patients with advance solid tumor is great unsolved challenge to the physicians. Efficacy of conventional treatment, such as surgery, radiotherapy and chemotherapy is limited. AS novel therapy, immunotherapy shows great prospects. Human iNKT cells can directly lysis tumor cells by a perforin-dependent mechanism,and intracellular granzyme B expression may ...

Phase

2.52 miles

Learn More »